Bridgebio Oncology TherapeutBBOT
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 31 institutions reported holding Bridgebio Oncology Therapeut (BBOT) in their 13F filings, unchanged from Q2 2024. 2 opened new positions and 2 sold out. The largest holders were Cormorant Asset Management, LP ($30.4M), BlackRock, Inc. ($15.7M) and Adage Capital Partners Gp, L.L.C. ($14.6M). 3 famous investors held it, including George Soros (0.1% of Soros Fund Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Bridgebio Oncology Therapeut
- Filed as
- HELIX ACQUISITION CORP II (Q3 2024)
- CUSIP
- G4444H101
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1.3M |
| Exits | 2 | $1.5M |
All 13F filers, Q2 2024 → Q3 2024: 149,438 shares bought and 155,993 shares sold, net −6,555 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Cormorant Asset Management, LP | 1.61% | No change | 2,909,000 | $30.4M |
| BlackRock, Inc. | 0.00% | — | 1,500,000 | $15.7M |
| Adage Capital Partners Gp, L.L.C. | 0.03% | No change | 1,400,000 | $14.6M |
| Citadel Advisors | 0.01% | Add +0.0% | 1,332,650 | $13.9M |
| Millennium Management | 0.01% | Add +1.2% | 1,130,317 | $11.8M |
| T. Rowe Price Associates Inc. | 0.00% | Reduce -0.3% | 1,127,598 | $11.8M |
| Sculptor Capital LP | 0.23% | No change | 705,000 | $7.4M |
| Farallon Capital Management, L.L.C. | 0.03% | No change | 600,000 | $6.3M |
| Silverarc Capital Management, LLC | 1.21% | Add +2.7% | 513,369 | $5.4M |
| Great Point Partners LLC | 1.58% | No change | 500,000 | $5.2M |
| Commodore Capital LP | 0.33% | No change | 500,000 | $5.2M |
| Perceptive Advisors LLC | 0.11% | No change | 500,000 | $5.2M |
| Soros Fund Management | 0.14% | No change | 475,000 | $5.0M |
| ADAR1 Capital Management, LLC | 0.71% | No change | 404,138 | $4.2M |
| T. Rowe Price Investment Management, Inc. | 0.00% | Reduce -0.6% | 397,649 | $4.2M |
| Laurion Capital Management LP | 0.21% | No change | 300,000 | $3.1M |
| Ghost Tree Capital, LLC | 1.07% | No change | 300,000 | $3.1M |
| Affinity Asset Advisors, LLC | 0.43% | No change | 250,000 | $2.6M |
| Octagon Capital Advisors LP | 0.42% | No change | 250,000 | $2.6M |
| Stempoint Capital LP | 0.63% | No change | 200,000 | $2.1M |
| Two Sigma Investments, LP | 0.00% | No change | 189,285 | $2.0M |
| Wellington Management Group LLP | 0.00% | No change | 184,670 | $1.9M |
| Acuta Capital Partners, LLC | 1.53% | Add +1.8% | 180,945 | $1.9M |
| TD Asset Management Inc | 0.00% | No change | 144,772 | $1.5M |
| Schonfeld Strategic Advisors LLC | 0.01% | New | 119,880 | $1.3M |
| Woodline Partners LP | 0.01% | No change | 103,247 | $1.1M |
| Moore Capital Management, LP | 0.03% | No change | 100,000 | $1.0M |
| Cowen and Company, LLC | 0.02% | Reduce -10.8% | 45,048 | $471K |
| Geode Capital Management, LLC | 0.00% | No change | 10,869 | $114K |
| UBS Group AG | 0.00% | New | 21 | $219 |
| JPMorgan Chase & Co. | 0.00% | No change | 4 | $42 |
"% of holder's portfolio" is BBOT's weight in each manager's 13F, not the share of Bridgebio Oncology Therapeut the manager owns.